GlassScriptPhysician profile
Madison Nash
NPI 1407451271
$3,552.98
in general payments reported to CMS, 2019-2025
27 companies · $1,924 in 2025
The $1,924 reported for 2025 was more than what 92% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $907 · 2024: $722 · 2025: $1,924.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,521 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,520.71 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,279.83 | 2023-2025 | |
| Janssen Biotech, INC. | $273.97 | 2023-2025 | Tremfya, Stelara, Simponi |
| Madrigal Pharmaceuticals | $253.41 | 2024-2025 | Rezdiffra, Resmetirom |
| Takeda Pharmaceuticals U.S.A., INC. | $164.28 | 2023-2025 | Eohilia, Entyvio, Gattex |
| Genzyme Corporation | $145.26 | 2023-2025 | |
| Novo Nordisk INC | $126.16 | 2023-2025 | Wegovy |
| Eisai INC. | $124.26 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $121.86 | 2025 | |
| Glaxosmithkline, LLC. | $120.86 | 2024 | Nucala |
| Intercept Pharmaceuticals, INC. | $107.44 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $100.97 | 2023 | Andexxa |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $99.97 | 2023 | |
| Medical Device Business Services, INC. | $99.74 | 2023 | Linx Reflux Management System |
| Pfizer INC. | $76.59 | 2024-2025 | |
| Gilead Sciences, INC. | $75.78 | 2025 | Livdelzi |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $49.47 | 2023-2024 | Trulance |
| Coloplast Corp | $45.66 | 2023 | Altis, Titan |
| Aimmune Therapeutics, INC. | $43.82 | 2025 | Zenpep |
| Ipsen Biopharmaceuticals, INC | $41.85 | 2025 | Iqirvo |
| Evoke Pharma, INC. | $41.05 | 2025 | |
| Ferring Pharmaceuticals INC. | $28.67 | 2024 | Rebyota |
| Merck Sharp & Dohme LLC | $28.34 | 2024 | Dificid |
| Ardelyx, INC. | $27.63 | 2025 | Ibsrela |
| Inspire Medical Systems, INC. | $22.72 | 2025 | Inspire |
| Celltrion USA INC. | $20.28 | 2024 | Vegzelma |
| Qol Medical, LLC | $18.35 | 2023 | Sucraid |
| Celgene Corporation | $14.76 | 2024 | Zeposia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Madison Nash listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.